Accepted Manuscript

Epidemiology of Hypertension in Canada: an Update

Raj S. Padwal, MD MSc, Asako Bienek, MHA, Finlay A. McAlister, MD, Norm RC. Campbell, MD

PII: S0828-282X(15)01306-9

DOI: 10.1016/j.cjca.2015.07.734

Reference: CJCA 1843

To appear in: Canadian Journal of Cardiology

Received Date: 6 June 2015
Revised Date: 16 July 2015
Accepted Date: 17 July 2015

Please cite this article as: Padwal RS, Bienek A, McAlister FA, Campbell NR, for the Outcomes Research Task Force of the Canadian Hypertension Education Program, Epidemiology of Hypertension in Canada: an Update, *Canadian Journal of Cardiology* (2015), doi: 10.1016/j.cjca.2015.07.734.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Epidemiology of Hypertension in Canada: an Update

Short Title: Epidemiology of Hypertension in Canada

Raj S Padwal MD MSc,^{1,2} Asako Bienek³ MHA, Finlay A McAlister¹ MD, Norm RC Campbell MD⁴, for the Outcomes Research Task Force of the Canadian Hypertension Education Program

Word Count: abstract 241; text 3193 Tables: 0; Figures: 5; Supplemental eFigures (electronic figures or published in an appendix): 5

Correspondence to:

Raj Padwal
Clinical Epidemiology, Clinical Pharmacology and General Internal Medicine
Associate Professor and Director, Hypertension Clinic
University of Alberta
5-134A Clinical Sciences Building
11350 - 83rd Ave
Edmonton, AB
T6G2G3
780-492-3686 (phone)
780-407-7277 (fax)
rpadwal@ualberta.ca

Conflict of Interest/Disclosures

In the past two years, RP has received honoraria for speaking or consulting from Servier, Medtronic, Abbott and Amgen and research funding from CVRx, Novo Nordisk, PharmaSmart, and Valencia Technologies. NC, AB, and FAM declare no commercial conflicts of interest.

Funding: None

Key Words: hypertension, blood pressure, epidemiology, prevalence, diabetes,

mortality, antihypertensive drugs

¹Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

²Alberta Diabetes Institute, Edmonton, Alberta, Canada

³Public Health Agency of Canada, Ottawa, Ontario, Canada

⁴Departments of Medicine, Community Health Sciences and of Physiology and Pharmacology, Libin Cardiovascular Institute, O'Brien Institute of Public Health, University of Calgary, Canada, 3280 Hospital Drive NW, Calgary Alberta, T2N 4Z6, Tel. No.: 001 403-210-7961, E-mail: ncampbel@ucalgary.ca

Download English Version:

https://daneshyari.com/en/article/5878722

Download Persian Version:

https://daneshyari.com/article/5878722

Daneshyari.com